Degarelix Acetate (Firmagon®)

Common name: Degarelix Acetate
Brand name: Firmagon®
 

What is Degarelix Acetate?

Degarelix Acetate is a gonadotropin-releasing hormone (GnRH) receptor antagonist used to treat advanced (metastatic) prostate cancer by blocking the release of testosterone.
 

How is Degarelix Acetate administered?

Degarelix Acetate is administered by subcutaneous injection in the abdominal area.
 

What are possible side effects of this treatment?

Everyone responds differently to hormone therapy – some experience many side effects while others experience very few. Below are some side effects experienced by those who received degarelix acetate. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
  • Back pain
  • Breast enlargement
  • Constipation
  • Difficulties sleeping
  • Fatigue
  • Frequent urination
  • Headaches
  • Hot flashes
  • Nausea
  • Pain / redness at site of injection
  • Reduced sex drive (low libido)


Is Degarelix Acetate covered in my province or territory?*

Degarelix acetate is covered by provincial drug programs in:
  • British Columbia
  • New Brunswick
  • Northwest Territories
  • Nova Scotia
  • Ontario
  • Prince Edward Island
  • Quebec
  • Saskatchewan

Degarelix acetate may be covered by provincial drug programs after individual review in:
  • Manitoba
​Degarelix acetate is not covered by provincial drug programs in:
  • ​Alberta
  • Newfoundland & Labrador
  • Yukon

Unknown if degarelix acetate is covered by provincial drug programs in:
  • Nunavut

Firmagon Care Program

Patient Assistance Programs are offered by pharmaceutical companies to provide medications and/or financial assistance to those who cannot afford to pay for their medicine.

Please call 1-855-982-6348 for more information and to see if you qualify for this program.


*Source: http://drugcoverage.ca/en-ca/search-results.aspx?ID=21330

Last Reviewed: July 2017




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
RFP: Content Development and Delivery of an Accredited Electronic Continuing Medical Education Course for Prostate Cancer Specialists

Prostate Cancer Canada invites applications from service providers interested in the development, promotion and delivery of an accredited electronic Continuing Medical Education course targeting prostate cancer specialists, including urologists.
More

Prostate Cancer Canada announces new President and CEO

Toronto, December 21, 2017 – After five successful years under the leadership and guidance of outgoing President and CEO, Rocco Rossi, Prostate Cancer Canada (PCC) is excited to announce the appointment of a most worthy successor in Peter Coleridge, past national CEO of the Canadian Mental Health Association and current national President and CEO of Big Brothers Big Sisters of Canada.
More

Université de Sherbrooke Researchers’ Findings Published in Cancer Research

Sherbrooke, November 16, 2017 – Prostate cancer, the most common cancer in men, affects one out of seven Canadian men.
More


Click here for news archive